EGFR and lung adenocarcinoma: While showing superior therapeutic efficacy for lung adenocarcinoma over erlotinib, the administration of afatinib at maximum tolerated doses is associated with a higher incidence of adverse events.76,77 Thus, the development of other binary EGFR inhibitors with low toxicity is of great clinical value.